XOMA Royalty (XOMA) Receivables - Other (2011 - 2024)
XOMA Royalty's (XOMA) quarterly Receivables - Other came in at $7.9 million in Q4 2024, down 44.76% quarter-over-quarter from $14.3 million in Q2 2024.
XOMA Royalty (XOMA) Receivables - Other (2011 - 2024) Analysis & Trends
XOMA Royalty has disclosed Receivables - Other across 9 years of filings, most recently posting $7.9 million for Q4 2024.
- Receivables - Other for Q4 2024 came in at $7.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $7.9 million (changed N/A YoY), and the FY2024 annual result was $7.9 million, down 44.42% from the prior year.
- Receivables - Other came in at $7.9 million for Q4 2024 at XOMA Royalty, down from $14.3 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $14.3 million in Q2 2024 to a low of $2.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.90 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Jun 30, 2024 | 14.30 Mn |
| Jun 30, 2024 | 14.30 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Sep 30, 2017 | 113,000.00 |
| Sep 30, 2017 | 113,000.00 |
| Jun 30, 2017 | 85,000.00 |
| Jun 30, 2017 | 85,000.00 |
| Mar 31, 2017 | 800,000.00 |
| Mar 31, 2017 | 800,000.00 |
| Dec 31, 2016 | 92,000.00 |
| Dec 31, 2016 | 92,000.00 |
| Dec 31, 2015 | 351,000.00 |
| Dec 31, 2015 | 351,000.00 |